Moleculin Biotech, Inc. Accounts Receivable
Moleculin Biotech, Inc. (MBRX) had Accounts Receivable of $1.00 thousand as of 2020-03-31, per its 10-Q filed 2020-05-11.
Discontinued › Balance Sheet › Assets › Assets, Current › Accounts and Financing Receivable, after Allowance for Credit Loss, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2020-05-11
- 2020-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $1.00K.
- 2019-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $1.00K.
- 2019-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $316.00K.
- 2018-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $56.00K.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2020-03-31 | $1.00K 10-Q · filed 2020-05-11 |
| 2019-12-31 | $1.00K 10-Q · filed 2020-05-11 |
| 2019-09-30 | $316.00K 10-Q · filed 2019-11-12 |
| 2018-12-31 | $56.00K 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |